

REMARKS/ARGUMENTS**I. Status of Claims and Formal Matters**

Claims 1, 5-6, 8-15, 18, 25, 28-30, 33, 36-37 and 39 are pending in this application. Claims 28-30, 36-37 and 39 are canceled with this response. Claim 1 is proposed to be amended. Upon entry of the proposed amendments, claims 1, 5-6, 8-15, 18, 25, and 33 are pending and under active consideration. Applicant respectfully requests entry of the proposed amendment and remarks into the file history the present application.

Claim 1 is proposed to be amended to remove subject matter directed to human growth hormone releasing hormone (hGHRH) and variants and salts thereof, thus rendering claim 1, as amended herein, identical in scope to claim 39 which the Examiner indicated in the Advisory Action would be allowable if rewritten in independent form.

The remaining claims depend from claim 1 and therefore incorporate all limitations of this claim. Accordingly, all claims, as amended herein, are limited to methods of treating MSA by administering hGH and its salts and variants, subject matter which the Examiner indicated in the Advisory Action is allowable.

Applicants respectfully request that the Examiner enter the amendments proposed herein and reconsider this application in view of these amendments.

CONCLUSION.

Applicants respectfully submit that the instant application is in good and proper order for allowance and early notification to this effect is solicited. The Examiner is hereby respectfully invited to contact the undersigned attorney at the telephone number listed below with any questions, comments, or suggestions relating to this application that may advance this application to allowance.

Respectfully submitted,
HOWREY LLP

Dated: April 14, 2010

By: /David W. Clough /
David W. Clough, Ph.D.
Registration No.: 36,107
Customer No.: 22930
Telephone No.: (312) 595-1408

HOWREY LLP
ATTN: Docketing Department
2941 Fairview Park Drive, Suite 200
Falls Church, VA 22042-2924
Facsimile No.: (703) 336-6950